Khan A, Tomita Y, Sykes M
Transplantation Biology Research Center, Surgical Service, Massachusetts General Hospital/Harvard Medical School, Boston 02129, USA.
Transplantation. 1996 Aug 15;62(3):380-7. doi: 10.1097/00007890-199608150-00014.
A nonmyeloablative conditioning regimen has recently been developed that allows allogeneic marrow engraftment with induction of permanent mixed chimerism and donor-specific tolerance across fully MHC-mismatched allogeneic barriers. We recently demonstrated that tolerance can be broken in these chimeras by administration of an anti-donor class I-specific monoclonal antibody that eliminates donor hematopoietic cells. We have now investigated the role of the thymus in the loss of tolerance observed when chimerism is eliminated in this manner. Mixed chimeras were prepared in B10 (H2b) recipients by treatment with depleting anti-CD4 and anti-CD8 mAbs, 3-Gy whole body irradiation, and 7-Gy thymic irradiation, followed by B10.A (H2a) bone marrow transplantation. Chimeras were thymectomized 7 weeks later, and were either untreated or were depleted of donor cells with anti-donor class I (Dd-specific) mAb 34-2-12. Control chimeras that were not thymectomized also received anti-donor monoclonal antibodies or no further treatment. Of the four groups, only euthymic animals that were depleted of donor antigen showed a loss of tolerance, as evidenced by rejection of B10.A skin grafts. In contrast to untreated control and thymectomized, anti-Dd-treated chimeras, these euthymic anti-Dd-treated chimeras showed significant recovery of Vbeta11+ T cells, which can recognize Mtv antigens presented by donor I-E molecules. The requirement for a thymus for loss of tolerance in the absence of donor antigen was verified in an adoptive transfer model, in which chimera (B10.A-->B10) spleen cells were depleted of donor-type cells ex vivo, adoptively transferred into B6 nu/nu mice, and then further depleted of donor-type antigen with monoclonal antibody treatment in vivo. These B6 nu/nu mice maintained donor-specific tolerance to B10.A skin grafts. The absence of active suppression as a potent mechanism of tolerance in long-term mixed chimeras was confirmed by the loss of mixed chimerism and of tolerance that was readily induced by injection of naive host-type spleen cells. Together, our results suggest that in mixed allogeneic chimeras, intrathymic clonal deletion, and not peripheral suppression or anergy, is the major mechanism maintaining donor-specific tolerance.
最近开发了一种非清髓性预处理方案,该方案可实现异基因骨髓植入,并诱导永久性混合嵌合体以及跨越完全主要组织相容性复合体(MHC)不匹配的异基因屏障的供体特异性耐受。我们最近证明,通过给予消除供体造血细胞的抗供体I类特异性单克隆抗体,可以打破这些嵌合体中的耐受性。我们现在研究了胸腺在以这种方式消除嵌合状态时所观察到的耐受性丧失中的作用。通过用耗竭性抗CD4和抗CD8单克隆抗体、3 Gy全身照射和7 Gy胸腺照射,随后进行B10.A(H2a)骨髓移植,在B10(H2b)受体中制备混合嵌合体。7周后对嵌合体进行胸腺切除,然后不进行处理或用抗供体I类(Dd特异性)单克隆抗体34-2-12清除供体细胞。未进行胸腺切除的对照嵌合体也接受抗供体单克隆抗体或不进行进一步处理。在这四组中,只有耗尽供体抗原的有胸腺动物表现出耐受性丧失,这通过对B10.A皮肤移植物的排斥反应得到证明。与未处理的对照和胸腺切除、抗Dd处理的嵌合体相反,这些有胸腺的抗Dd处理的嵌合体显示Vbeta11 + T细胞显著恢复,这些细胞可以识别由供体I-E分子呈递的Mtv抗原。在过继转移模型中证实了在没有供体抗原的情况下耐受性丧失对胸腺的需求,在该模型中,将嵌合体(B10.A→B10)脾细胞在体外耗尽供体型细胞,过继转移到B6 nu/nu小鼠中,然后在体内用单克隆抗体处理进一步耗尽供体型抗原。这些B6 nu/nu小鼠对B10.A皮肤移植物保持供体特异性耐受。通过混合嵌合状态的丧失以及通过注射幼稚宿主型脾细胞容易诱导的耐受性丧失,证实了在长期混合嵌合体中不存在作为一种有效耐受机制的主动抑制。总之,我们的结果表明,在混合异基因嵌合体中,胸腺内克隆缺失而非外周抑制或无反应性是维持供体特异性耐受的主要机制。